CF101 1 mg + CF101 2 mg + Placebo + MTX
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Rheumatoid Arthritis
Conditions
Rheumatoid Arthritis
Trial Timeline
Oct 30, 2017 → Nov 30, 2020
NCT ID
NCT02647762About CF101 1 mg + CF101 2 mg + Placebo + MTX
CF101 1 mg + CF101 2 mg + Placebo + MTX is a phase 3 stage product being developed by Can Fite Biopharma for Rheumatoid Arthritis. The current trial status is terminated. This product is registered under clinical trial identifier NCT02647762. Target conditions include Rheumatoid Arthritis.
What happened to similar drugs?
20 of 20 similar drugs in Rheumatoid Arthritis were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
17
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02647762 | Phase 3 | Terminated |
Competing Products
20 competing products in Rheumatoid Arthritis